Ardelyx, Inc. (FRA:41X)
4.959
-0.139 (-2.73%)
Last updated: Dec 1, 2025, 8:19 AM CET
Ardelyx Revenue
Ardelyx had revenue of $110.33M USD in the quarter ending September 30, 2025, with 12.30% growth. This brings the company's revenue in the last twelve months to $398.23M, up 58.12% year-over-year. In the year 2024, Ardelyx had annual revenue of $333.62M with 168.06% growth.
Revenue (ttm)
$398.23M
Revenue Growth
+58.12%
P/S Ratio
3.44
Revenue / Employee
$1.01M
Employees
395
Market Cap
1.17B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
| Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
| Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
| Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
| Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
| Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
| Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
| Dec 31, 2017 | 42.00M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
| Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
| Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
| Dec 31, 2012 | 5.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
Ardelyx News
- 24 days ago - Real-World Evidence Studies of XPHOZAH (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week - Wallstreet:Online
- 24 days ago - Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week - GlobeNewsWire
- 26 days ago - Ardelyx to Participate at the Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 26 days ago - Ardelyx: Impressive Q3 Record Growth - Why I Buy - Seeking Alpha
- 27 days ago - Ardelyx: A Long Overdue Rally - Seeking Alpha
- 27 days ago - Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference - GlobeNewsWire
- 4 weeks ago - Citigroup Raises Ardelyx (ARDX) Price Target to $11.00 with Buy Rating | ARDX Stock News - GuruFocus
- 4 weeks ago - Ardelyx (ARDX) Receives a Boost in Price Target from TD Cowen | ARDX Stock News - GuruFocus